Vaccines

Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.

The CDC on Thursday recommended updated COVID-19 vaccines for the 2024-2025 respiratory season, and a newly approved 21-valent pneumococcal conjugate vaccine for adults.

A two-dose series of a hepatitis B vaccine with a CpG adjuvant resulted in a more than 90% response rate among health care workers previously classified as nonresponders, researchers found.

Moderna announced positive phase 3 trial data for its combination COVID-19 and influenza vaccine this week, suggesting a combination shot for respiratory infections is on the way.

In late May, the FDA announced approval of Moderna's mResvia, marking the third vaccine approved for respiratory syncytial virus and first time messenger RNA technology has been used for preventing a disease other than COVID-19.

CHICAGO — Combining an mRNA-based cancer vaccine with standard-of-care pembrolizumab significantly improved RFS and distant metastasis-free survival among patients with resected high-risk melanoma, study results showed.

A third dose of COVID-19 vaccine can boost serological and T-cell response among most patients who are immunocompromised, according to data published in The Lancet Rheumatology.

TORONTO — Trust in vaccines declined among parents and teenagers over a period of time that included the COVID-19 pandemic, according to survey results presented at the Pediatric Academic Societies Meeting.

HOUSTON — Peter J. Hotez, MD, PhD, has been working in vaccine development for more than 40 years.

A personalized cancer vaccine produced T-cell responses in certain patients with head and neck squamous cell carcinoma, according to results from a randomized study presented at American Association for Cancer Research Annual Meeting.